Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 May 24

PMID 32443915

Citations 16

Authors

Shian-Ren Lin

Ntlotlang Mokgautsi

Yen-Nien Liu

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is one of the most prevalent and malignant cancer types in men, which causes more than three-hundred thousand cancer death each year. At late stage of PCa progression, bone marrow is the most often metastatic site that constitutes almost 70% of metastatic cases of the PCa population. However, the characteristic for the osteo-philic property of PCa is still puzzling. Recent studies reported that the Wnt and Ras signaling pathways are pivotal in bone metastasis and that take parts in different cytological changes, but their crosstalk is not well studied. In this review, we focused on interactions between the Wnt and Ras signaling pathways during each stage of bone metastasis and present the fate of those interactions. This review contributes insights that can guide other researchers by unveiling more details with regard to bone metastasis and might also help in finding potential therapeutic regimens for preventing PCa bone metastasis.

Citing Articles

Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).

Xu Y, Zhang G, Liu Y, Liu Y, Tian A, Che J Int J Oncol. 2024; 65(5).

PMID: 39301646 PMC: 11419411. DOI: 10.3892/ijo.2024.5692.

Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking.

Li J, Wang X, Xue L, He Q Heliyon. 2024; 10(12):e33103.

PMID: 39022084 PMC: 11253540. DOI: 10.1016/j.heliyon.2024.e33103.

Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers.

Lan H, Wu B, Jin K, Chen Y Front Endocrinol (Lausanne). 2024; 14:1260491.

PMID: 38260135 PMC: 10800370. DOI: 10.3389/fendo.2023.1260491.

Unlocking the role of non-coding RNAs in prostate cancer progression: exploring the interplay with the Wnt signaling pathway.

Bu T, Li L, Tian J Front Pharmacol. 2023; 14:1269233.

PMID: 37829301 PMC: 10565042. DOI: 10.3389/fphar.2023.1269233.

WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice.

Xue W, Cai L, Li S, Hou Y, Wang Y, Yang D Discov Oncol. 2023; 14(1):136.

PMID: 37486552 PMC: 10366069. DOI: 10.1007/s12672-023-00739-7.

References

Du W, Fang Q, Chen Y, Teng J, Xiao Y, Xie P . Effect of silencing the T‑Box transcription factor TBX2 in prostate cancer PC3 and LNCaP cells. Mol Med Rep. 2017; 16(5):6050-6058. PMC: 5865808. DOI: 10.3892/mmr.2017.7361. View

Giancotti F . Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-64. PMC: 4354734. DOI: 10.1016/j.cell.2013.10.029. View

Wong S, Mohamad N, Giaze T, Chin K, Mohamed N, Ima-Nirwana S . Prostate Cancer and Bone Metastases: The Underlying Mechanisms. Int J Mol Sci. 2019; 20(10). PMC: 6567184. DOI: 10.3390/ijms20102587. View

Hormaechea-Agulla D, Jimenez-Vacas J, Gomez-Gomez E, L-Lopez F, Carrasco-Valiente J, Valero-Rosa J . The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB J. 2017; 31(11):4682-4696. DOI: 10.1096/fj.201601264RRR. View

Hasan D, Gamen E, Tarboush N, Ismail Y, Pak O, Azab B . PKM2 and HIF-1α regulation in prostate cancer cell lines. PLoS One. 2018; 13(9):e0203745. PMC: 6138389. DOI: 10.1371/journal.pone.0203745. View

Wozney J, Antonarakis E . Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 2014; 33(2-3):581-94. PMC: 4090293. DOI: 10.1007/s10555-013-9475-z. View

Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S . Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145. Int J Oncol. 2013; 42(4):1473-81. DOI: 10.3892/ijo.2013.1825. View

Chang A, Chen P, Lin Y, Su C, Liu J, Lin T . Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. Cancer Lett. 2018; 426:47-56. DOI: 10.1016/j.canlet.2018.03.050. View

Rieunier G, Wu X, Macaulay V, Lee A, Weyer-Czernilofsky U, Bogenrieder T . Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis. Clin Cancer Res. 2019; 25(12):3479-3485. DOI: 10.1158/1078-0432.CCR-18-2697. View

10.

Hu C, Chen B, Zhou Y, Shan Y . High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy. Cancer Cell Int. 2017; 17:45. PMC: 5387234. DOI: 10.1186/s12935-017-0411-0. View

11.

Browne A, Gobel A, Thiele S, Hofbauer L, Rauner M, Rachner T . p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death Dis. 2016; 7:e2119. PMC: 4849158. DOI: 10.1038/cddis.2016.32. View

12.

Regad T . Targeting RTK Signaling Pathways in Cancer. Cancers (Basel). 2015; 7(3):1758-84. PMC: 4586793. DOI: 10.3390/cancers7030860. View

13.

Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J . Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow. Cancer Res. 2016; 76(8):2453-64. DOI: 10.1158/0008-5472.CAN-15-2340. View

14.

Jeter C, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T . NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011; 30(36):3833-45. PMC: 3140601. DOI: 10.1038/onc.2011.114. View

15.

Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, Moran S . Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene. 2013; 33(21):2807-13. PMC: 4031636. DOI: 10.1038/onc.2013.239. View

16.

Byrne N, Summers M, McDonald M . Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities. JBMR Plus. 2019; 3(3):e10125. PMC: 6419605. DOI: 10.1002/jbm4.10125. View

17.

Chakravarthi B, Chandrashekar D, Balasubramanya S, Robinson A, Carskadon S, Rao U . Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate. 2018; 78(16):1311-1320. DOI: 10.1002/pros.23704. View

18.

Dang D, Chen X, Feng J, Torbenson M, Dang L, Yang V . Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene. 2003; 22(22):3424-30. PMC: 2275074. DOI: 10.1038/sj.onc.1206413. View

19.

Xia Y, Shen S, Verma I . NF-κB, an active player in human cancers. Cancer Immunol Res. 2014; 2(9):823-30. PMC: 4155602. DOI: 10.1158/2326-6066.CIR-14-0112. View

20.

Wa Q, Li L, Lin H, Peng X, Ren D, Huang Y . Downregulation of miR‑19a‑3p promotes invasion, migration and bone metastasis via activating TGF‑β signaling in prostate cancer. Oncol Rep. 2017; 39(1):81-90. PMC: 5783607. DOI: 10.3892/or.2017.6096. View